INVO Fertility continues its transformation from primarily a medical device company into a healthcare services provider focused on assisted reproductive technology (ART) clinics. The February 2026 acquisition of Family Beginnings marks another step in scaling its fertility clinic footprint, complementing prior acquisitions such as Wisconsin Fertility Institute. Recent SEC disclosures confirm a technical restatement of prior periods driven by derivative and preferred stock classification errors, which did not affect core revenue or operating losses. The firm’s proprietary INVOcell device underpins its differentiated approach in the competitive ART market, while expansion into ancillary fertility therapies and telehealth broadens service offerings. Liquidity challenges and regulatory risks remain material constraints as the company seeks to leverage clinic-based cash flows toward profitability.